84. サルコイドーシス Sarcoidosis Clinical trials / Disease details
臨床試験数 : 149 / 薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2007-005117-18-AT (EUCTR) | 03/04/2008 | 04/03/2008 | Safety and efficacy study of bosentan in progressive pulmonary sarcoidosis - BOPSAC | Safety and efficacy study of bosentan in progressive pulmonary sarcoidosis - BOPSAC | Progressive pulmonary sarcoidosis MedDRA version: 9.1;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis | Trade Name: Tracleer Product Name: Bosentan | Medical University of Vienna, Department of Clinical Pharmacology | NULL | Not Recruiting | Female: yes Male: yes | Austria | ||||
| 2 | EUCTR2006-005361-19-GB (EUCTR) | 09/03/2007 | 17/12/2006 | Evaluation of the efficacy of the dual endothelin 1 receptor antagonist Bosentan in the treatment of Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and in the treatment of Pulmonary Hypertension secondary to sarcoidosis | Evaluation of the efficacy of the dual endothelin 1 receptor antagonist Bosentan in the treatment of Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and in the treatment of Pulmonary Hypertension secondary to sarcoidosis | Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and secondary to Sarcoid Patients devolop pulmonary hypertension for various reasons, two common causes are Chronic Obstructive Pulmonary disease and Sarcoid. Once developed it may go on to cause right heart failure and severe breathlessness and eventually death. We believe that the use of bosentan may lower the pulmonary hypertension and improve symptoms. MedDRA version: 8.1;Level: LLT;Classification code 10037400;Term: Pulmonary hypertension | Trade Name: Tracleer Product Name: tracleer INN or Proposed INN: Bosentan monohydrate | St Georges Hospital | NULL | Not Recruiting | Female: yes Male: yes | 45 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes | United Kingdom |